The research was led by Professor Junbo Ge and Professor Aijun Sun of Zhongshan Hospital, Fudan University, in collaboration with affiliated institutions. The investigators examined whether “eustress”—a positive form of environmental and psychological stimulation—could influence the outcome of chemotherapy-induced cardiac injury. In animal experiments, they used an enriched environment, or EE, a standard research model that provides increased sensory, cognitive and physical stimulation compared with conventional housing. Previous studies have linked EE exposure to improved recovery after myocardial infarction and stroke, but its effects during simultaneous chemotherapy and tumor growth had not been clearly defined.

Doxorubicin can injure cardiac muscle through several overlapping mechanisms, including oxidative stress, mitochondrial dysfunction and inflammatory activation. Because the heart has limited regenerative capacity, repeated exposure can lead to progressive loss of cardiomyocytes, impaired contraction and, in severe cases, heart failure. This toxicity creates a difficult clinical balance: increasing the chemotherapy dose may improve tumor control, but it can also increase the risk of permanent cardiac damage. According to the study, the immune-inflammatory response was a central process altered by environmental enrichment in mice receiving doxorubicin.

The researchers found that EE selectively reduced the accumulation of pro-inflammatory Ly6C-high monocytes and macrophages in cardiac tissue. These immune cells can migrate into injured organs and amplify inflammation by releasing cytokines and other signaling factors. Among the molecular changes observed in the enriched-environment animals, the chemokine CCL2 emerged as a critical regulator. CCL2, also known as monocyte chemoattractant protein-1, helps recruit monocytes from the circulation into tissues. Lower CCL2 levels in the heart were associated with less inflammatory infiltration and reduced myocardial injury after doxorubicin exposure.

Genetic experiments supported a causal role for this pathway. When Ccl2 was deleted in mice, the protective effect of the enriched environment against doxorubicin-related cardiac damage was substantially weakened. The reduction in Ly6C-high macrophage infiltration was also diminished. These findings suggest that CCL2 is not merely a marker of inflammation in this model, but an important molecular link through which environmental stimulation influences the heart’s response to chemotherapy.

The study further connected this process to brain signaling. Disruption of brain-derived neurotrophic factor, or BDNF, in the hypothalamus reversed the environmental enrichment-associated reduction in cardiac Ccl2 expression and abolished much of the observed cardioprotection. The hypothalamus is a key region for coordinating neural, hormonal and physiological responses to environmental conditions. BDNF is involved in neuronal plasticity and adaptive responses to stimulation. The results therefore point to a signaling route in which environmental inputs affect hypothalamic BDNF, which then influences CCL2-driven inflammation in the heart.

The benefits of EE were not confined to cardiac tissue. In tumor-bearing mice treated with doxorubicin, the enriched environment also enhanced chemotherapy’s ability to suppress tumor growth. The researchers linked this effect to changes in Ccl2 expression within the tumor microenvironment, the complex network of immune cells, blood vessels and connective tissue surrounding malignant cells. Reduced Ccl2 signaling was associated with fewer granulocytic myeloid-derived suppressor cells, or G-MDSCs, and fewer M2-type tumor-associated macrophages, both of which can suppress anti-tumor immunity.

At the same time, the tumors of animals exposed to EE showed increased proportions of cytotoxic CD8-positive T cells and M1-type macrophages. CD8-positive T cells can directly recognize and destroy malignant cells, while M1-polarized macrophages generally support inflammatory and anti-tumor activity. By shifting the immune balance away from suppressive cell populations and toward cells capable of attacking cancer, environmental enrichment appeared to remodel the tumor microenvironment and improve the response to doxorubicin. The study thus describes a dual effect: reduced inflammation in the heart alongside stronger immune activity against the tumor.

The investigators refer to this integrated mechanism as a “hypothalamus-heart-tumor axis.” The concept suggests that environmental and emotional conditions can influence cancer treatment outcomes through coordinated neuroimmune signaling rather than through an isolated effect on a single organ. Although the findings come from experimental models and do not yet establish whether comparable benefits occur in patients, they raise the possibility that carefully designed non-pharmacological interventions could complement cardio-oncology care. Such approaches might eventually include structured physical, cognitive and social stimulation, although their safety and effectiveness would require rigorous clinical testing.

The study identifies CCL2 as a potential therapeutic target at the intersection of chemotherapy-related cardiac injury and tumor immunity. It also expands the biological understanding of how positive environmental conditions may regulate inflammation during serious disease. For patients receiving doxorubicin, the long-term goal is to preserve cardiac function without weakening cancer treatment. The new findings suggest that influencing neuroimmune pathways could offer one route toward that goal, while emphasizing that translation from enriched-environment experiments in mice to clinical practice remains an important challenge.

Subject of Research: The effects of environmental eustress on doxorubicin-induced cardiotoxicity and tumor growth.

Article Title: “Environmental eustress inhibits CCL2 to overcome doxorubicin-induced cardiotoxicity and alleviate tumor growth”

Web References: https://doi.org/10.1016/j.scib.2026.06.055

References: Science Bulletin, DOI: 10.1016/j.scib.2026.06.055

Image Credits: © Science Bulletin

Keywords: doxorubicin, cardiotoxicity, environmental enrichment, eustress, CCL2, BDNF, hypothalamus-heart-tumor axis, macrophages, tumor microenvironment, cancer immunology, cardio-oncology

The significance of HCC cannot be overstated, as it ranks as one of the most prevalent types of liver cancer worldwide. This malignancy poses a serious health threat, particularly in regions with high rates of hepatitis infections and alcohol-related liver disease. The development of effective treatment regimens is imperative, especially considering the typically late diagnosis of this aggressive cancer. The findings from An and colleagues underscore the importance of understanding molecular mechanisms driving HCC progression, potentially paving the way for novel therapeutic interventions.

SMIM45-107aa represents a new class of peptides that could be instrumental in altering the progression of various cancers. The structure and function of this peptide are rooted deeply in its ability to activate the MTDH signaling pathways, thereby fostering an environment conducive to tumor growth and aggressiveness. This discovery is monumental as it not only elucidates the role of this specific peptide in oncogenesis but also opens the floodgates for further research into peptide-based cancer therapies.

Moreover, the implications of peptide therapeutics in oncology extend beyond just HCC. The versatility of peptides as modulators of various biological processes suggests that they may be harnessed to tackle other forms of cancer as well. The promise that SMIM45-107aa shows could set a precedent for the development of peptide derivatives that enhance therapeutic efficacy while minimizing adverse effects in cancer patients.

The study meticulously integrates experimental methodologies to ascertain the functionality of SMIM45-107aa. Through in vitro and in vivo experiments, the research team evaluated its effects on HCC cell lines and established animal models. The results were significantly indicative of the peptide’s ability to enhance MTDH activity, thereby promoting cell proliferation and migration, fundamental characteristics of cancer aggressiveness.

An intriguing aspect of this research is the dual potential of SMIM45-107aa. Not only does it act as a promoter of HCC progression, but its derivative forms may also serve as therapeutic agents. The prospects of redesigning SMIM45-107aa into a derivative capable of inhibiting HCC presents an exciting avenue for innovative treatment modalities. By chemically altering the peptide’s structure, scientists could create variations that selectively disrupt the pathways activated by MTDH, hampering tumor growth.

Additionally, understanding the signaling networks influenced by SMIM45-107aa enhances the broader comprehension of tumor biology. The signaling pathways activated by oncogenes like MTDH are complex and involve numerous feedback loops and interactions with other signaling molecules. This multifaceted behavior is crucial in devising combination therapies that utilize both peptide-based strategies and conventional chemotherapy, ultimately improving patient outcomes.

The interplay between peptides like SMIM45-107aa and established oncogenes shapes the future landscape of cancer treatment. Beyond the immediate implications for HCC, the paradigms developed through this research could have implications for understanding other cancer types where MTDH or similar pathways are implicated. The interconnectedness of signaling pathways in cancer illustrates the necessity of a holistic approach in treatment, advocating for the integration of diverse therapeutic modalities.

As researchers venture deeper into the landscape of peptide therapeutics, the demand for understanding their pharmacokinetics and biodistribution also rises. Ensuring that any therapeutic peptide achieves optimal levels in tumor tissues while sparing healthy cells is fundamental for minimizing side effects. The design of SMIM45-107aa derivatives could be refined to enhance their stability and specificity for tumor cells, thus improving therapeutic windows.

In summary, the work by An and colleagues casts a promising light on the potential of peptide-based interventions for HCC. By shedding light on the mechanisms by which SMIM45-107aa operates, the study identifies a pivotal piece in the complex puzzle of cancer biology. It is imperative that future studies build upon these findings to harness the full potential of peptides in cancer therapy.

As we move forward, the insights from this research will resonate within the scientific community, inspiring further investigation into the nuanced interplay between peptides and cancer progression. The implications of unlocking the secrets of peptides like SMIM45-107aa epitomize the forward momentum towards more targeted, effective cancer treatments, marking an exciting new chapter in the realm of oncology.

With the rise of cancer incidence worldwide, it is crucial to advance research in this field energetically. Opportunities for peptide-based therapies present a window of hope for patients battling liver cancer and possibly other malignancies linked to MTDH signaling pathways. The future of cancer treatment may well lie in the intricate dance between peptides and the complex signaling networks that define cellular behavior in tumors.

As this field continues to evolve, the research community eagerly anticipates the development of innovative strategies that incorporate findings like those of An et al. into clinically relevant therapies. The findings herald a future where peptides offer not just explanations for cancer progression but tangible solutions capable of changing the treatment landscape entirely.

The integration of peptide research into mainstream oncology represents the bounding frontier of cancer therapy. With SMIM45-107aa, the possibilities are only just beginning to unfold, inviting a rich tapestry of research and discovery that could significantly alter the trajectory of cancer outcomes in liver and beyond.

Subject of Research: The effect of the peptide SMIM45-107aa on HCC progression via MTDH pathways.

Article Title: A novel peptide SMIM45-107aa promotes HCC progression via MTDH pathways and its anticancer peptide derivative.

Article References:

An, Y., Shi, X., Huang, W. et al. –A novel peptide SMIM45-107aa promotes HCC progression via MTDH pathways and its anticancer peptide derivative.
J Transl Med 23, 1266 (2025). https://doi.org/10.1186/s12967-025-07179-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07179-7

Keywords: HCC, SMIM45-107aa, MTDH, peptide therapy, cancer progression.